TY - JOUR
T1 - Plasma neuropeptide Y concentrations in combat exposed veterans
T2 - Relationship to trauma exposure, recovery from PTSD, and coping
AU - Yehuda, Rachel
AU - Brand, Sarah
AU - Yang, Ren Kui
N1 - Funding Information:
This work was supported by a VA Merit Review Grant (RY), and, in part, by a grant (Grant No. 5 M01 RR00071) for the Mount Sinai General Clinical Research Center from the National Institute of Health. We thank Dr. Julia Golier for providing medical clearance, Dr. Lisa Tischler for supervision of diagnostic assessments and consensus conferences, Dr. Linda Bierer for helpful comments on the manuscript, and Karina Stavitsky for coordinating this study.
PY - 2006/4/1
Y1 - 2006/4/1
N2 - Background: There is emerging interest in examining the role of plasma neuropeptide Y (NPY) as a protective stress factor. Methods: To further investigate this possibility, plasma NPY was measured in 11 nonexposed veterans, 11 combat-exposed veterans without posttraumatic stress disorder (PTSD), and 12 veterans with current PTSD. Results: A significant group difference in plasma NPY (F2,31 = 5.16, p = .012) was observed, reflecting higher NPY levels in exposed veterans without PTSD than in nonexposed but comparable levels in veterans with current PTSD. Among those without current PTSD, veterans with past PTSD had higher NPY levels than those without past PTSD (t9 = 2.71, p = .024). After controlling for all other variables, NPY levels were significantly predicted by extent of symptom improvement and lower combat exposure and significant at a trend level with positive coping. Conclusions: Plasma NPY levels may represent a biologic correlate of resilience to or recovery from the adverse effects of stress.
AB - Background: There is emerging interest in examining the role of plasma neuropeptide Y (NPY) as a protective stress factor. Methods: To further investigate this possibility, plasma NPY was measured in 11 nonexposed veterans, 11 combat-exposed veterans without posttraumatic stress disorder (PTSD), and 12 veterans with current PTSD. Results: A significant group difference in plasma NPY (F2,31 = 5.16, p = .012) was observed, reflecting higher NPY levels in exposed veterans without PTSD than in nonexposed but comparable levels in veterans with current PTSD. Among those without current PTSD, veterans with past PTSD had higher NPY levels than those without past PTSD (t9 = 2.71, p = .024). After controlling for all other variables, NPY levels were significantly predicted by extent of symptom improvement and lower combat exposure and significant at a trend level with positive coping. Conclusions: Plasma NPY levels may represent a biologic correlate of resilience to or recovery from the adverse effects of stress.
KW - Coping
KW - Neuropeptide Y
KW - Neurotransmitters
KW - Posttraumatic stress disorder
KW - Resilience
UR - http://www.scopus.com/inward/record.url?scp=33644817491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644817491&partnerID=8YFLogxK
U2 - 10.1016/j.biopsych.2005.08.027
DO - 10.1016/j.biopsych.2005.08.027
M3 - Article
C2 - 16325152
AN - SCOPUS:33644817491
SN - 0006-3223
VL - 59
SP - 660
EP - 663
JO - Biological psychiatry
JF - Biological psychiatry
IS - 7
ER -